PTC THERAPEUTICS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
PTC Therapeutics develops and markets drugs for rare genetic disorders, including treatments for Duchenne muscular dystrophy and spinal muscular atrophy, alongside a pipeline of RNA-targeted and gene therapy candidates for other rare diseases.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| SCHMERTZLER MICHAELDirector | Sell | $155K | 2,447at $63.38 | Oct 7, 2026 |
| SCHMERTZLER MICHAELDirector | Sell | $3K | 53at $63.95 | Oct 7, 2026 |
| Boulding Mark ElliottEXEC. VP AND CLO | Sell | $105K | 1,638at $64.03 | Oct 5, 2026 |
| Boulding Mark ElliottEXEC. VP AND CLO | Sell | $28K | 435at $64.16 | Oct 6, 2026 |
| SCHMERTZLER MICHAELInsider | Sell | $851K | 11,890at $71.55 | Aug 27, 2026 |
| SCHMERTZLER MICHAELInsider | Sell | $500K | 6,874at $72.74 | Aug 26, 2026 |
| SCHMERTZLER MICHAELInsider | Sell | $412K | 5,626at $73.18 | Aug 26, 2026 |
| SCHMERTZLER MICHAELInsider | Sell | $44K | 610at $72.22 | Aug 27, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PTCT activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.